Custirsen

Prostate Cancer

Achieve Life Sciencesnucleic_acidPhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 59/ 100

Competitive context

514 Active assets in the Prostate Cancer cohort.

Asset / Sponsor	Phase	Rating
Avodart Bay State Clinical Trials, Inc.	Phase 4	BBB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Degarelix Bayer	Phase 4	BBB
PROPOFOL Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Fluciclovine NRG Oncology	Phase 4	BB

View all 50 →

Same molecule, other indications

Custirsen is also rated in:

Hormone Refractory Prostate CancerDormant

B

Indicative ·

60 / 100

castration-resistant prostate carcinomaDormant

B

Indicative ·

60 / 100

non-small cell lung carcinomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.